Radioembolization for Hepatocellular Carcinoma: A Nationwide 10-Year Experience

Use of TARE in patients with HCC has been increasing. Several factors are significantly associated with a less favorable outcome after TARE, including male sex, large tumors, and extrahepatic disease. These data can be used for designing future radioembolization trials.